Literature DB >> 206632

Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice.

G A Olsen, E R Kern, J C Overall.   

Abstract

The effect of treatment with exogenous interferon was compared with those of two interferon inducers, polyriboinosinic-polyribocytidylic acid [poly(I) . poly(C)] and poly(I) . poly(C)-poly-L-lysine complex [poly(ICLC)], in three model Herpesvirus hominis type 2 infections of mice. After intraperitoneal inoculation of H. hominis type 2, all drugs significantly protected animals against death and increased the mean day of death when administered as late as 48 hr after viral inoculation. With intranasal inoculation of H. hominis type 2, pretreatment with poly (I) . poly (C) and poly (ICLC) increased the mean day of death; however, no drug prevented death. In mice inoculated intravaginally, local treatment with exogenous interferon or poly(I) . poly(C) appeared to reduce the mean titers of virus in genital secretions and resulted in earlier clearance of infection in some animals. Systemic treatment of genital H. hominis type 2 infections with all drugs resulted in significant numbers of infected animals surviving the infection, although the mean titers of virus in genital secretions were unchanged. Therapeutic efficacy varied depending on the route of viral inoculation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 206632     DOI: 10.1093/infdis/137.4.428

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Role of interferon in mice in protection against influenza A virus by bacterial ribosomes together with membranal glycoproteins of Klebsiella pneumoniae as adjuvant.

Authors:  D Robert; J P Quillon; B Ivanoff; Y Beaudry; R Fontanges; G Normier; A M Pinel; L D D'hinterland
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

2.  Genital herpes.

Authors: 
Journal:  Br Med J       Date:  1980-06-07

3.  Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes.

Authors:  L R Crane; H B Levy; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  Comparative activities of selected combinations of acyclovir, vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculated mice.

Authors:  L R Crane; D A Milne; J C Sunstrum; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

5.  Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice.

Authors:  E B Fraser-Smith; D A Eppstein; Y V Marsh; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

6.  Effect of pyran on latency after herpes simplex virus infections.

Authors:  P S Morahan; P F Cline; M C Breinig; B K Murray
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

7.  The effect of temperature on production and function of bovine interferons.

Authors:  G J Letchworth; L E Carmichael
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

8.  Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

9.  Use of viral infections in animal models to assess changes in the immune system.

Authors:  E R Kern
Journal:  Environ Health Perspect       Date:  1982-02       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.